Biologics for psoriasis in COVID-19 era: What do we know?

Dermatol Ther. 2020 Jul;33(4):e13467. doi: 10.1111/dth.13467. Epub 2020 Jun 15.

Authors

Matteo Megna¹, Maddalena Napolitano², Cataldo Patruno³, Gabriella Fabbrocini¹

Affiliations

¹ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
² Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
³ Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
Biological Products* / adverse effects
COVID-19
Coronavirus Infections*
Humans
Immunosuppressive Agents
Pandemics*
Pneumonia, Viral*
Psoriasis* / diagnosis
Psoriasis* / drug therapy
SARS-CoV-2

Substances

Biological Products
Immunosuppressive Agents